GSK replaces R&D head with industry veteran, as incumbent resigns to take up govt post
UK pharma major GlaxoSmithKline (LSE: GSK) today confirmed that its president of R&D, Dr Patrick Vallance, has resigned, as rumored last week.
Dr Vallance has taken up the post of UK government’s chief scientific adviser and head of the government’s office for science. He will be responsible for providing scientific advice to the Prime Minister and advising the government on aspects of policy on science and technology. He will leave GSK at the end of March 2018 to take up his new role.
Meantime, Dr Hal Barron has been appointed chief scientific officer and president, R&D, GSK. He has also been appointed as an executive director to the GSK Board. Dr Barron will assume his new role and join the board on January 1, 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze